UNSPSC 51433407: Moexipril hydrochloride

This classification denotes an ace inhibitor with the molecular formula C27H34N2O7.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1UMG3UH45, chemically known as 3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, monohydrochloride, (3s-(2(r*(r*)),3r*))- but more generally known as moexipril hydrochloride, which bears US NIH Compound Identifier 54889.

UNSPSC 51433407 Moexipril hydrochloride is a Commodity code representing branded and generic prescription pharmaceuticals supplied directly to state and local health agencies, emergency responders, and state Medicaid programs. State and local governments purchase moexipril and related antihypertensive medications through competitive procurement channels to stock emergency medical supplies, institutional pharmacy formularies, and state health benefit programs. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances coordinating procurement across participating jurisdictions and member agencies (Minnesota Multistate Cooperative Purchasing Alliance). The code spans both emergency life-support medications and routine pharmacy benefit management, with vendors required to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, expiration-date warranties, and OSHA hazard communication documentation.

Recent activity appears concentrated in Texas and Minnesota, with a standalone procurement from the City of Tampa, Florida. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188) due April 8, 2026, for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a small local business enterprise (SLBE) sheltered market designation offering a 5 percent bid discount not to exceed $10,000. The Minnesota Department of Administration issued an RFP through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, establishing multiple contracts effective July 1, 2026, with pricing weighted at 75 percent and administrative fees of 3 percent on all purchases. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, representing exploratory procurement strategy development rather than a binding solicitation.